Use of advanced treatment technologies among men at low risk of dying from prostate cancer

JAMA

Volumn 309, Issue 24, 2013, Pages 2587-2595

  Jacobs, Bruce L ^a,b   Zhang, Yun ^b   Schroeck, Florian R ^a,b   Skolarus, Ted A ^a,b,c   Wei, John T ^b   Montie, James E ^a,b   Gilbert, Scott M ^d   Strope, Seth A ^e   Dunn, Rodney L ^b   Miller, David C ^a,b   Hollenbeck, Brent K ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; DYING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

EID: 84879353719     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6882     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Roehrig C, Miller G, Lake C, Bryant J. National health spending by medical condition, 1996-2005. Health Aff (Millwood). 2009;28(2):w358-w367.
3. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302(14):1557-1564.
4. Jacobs BL, Zhang Y, Skolarus TA, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer [published online July 6, 2012]. Eur Urol . doi:10.1016/j.eururo.2012.06.055.
5. Barbash GI, Glied SA. New technology and health care costs: the case of robot-assisted surgery. N Engl J Med. 2010;363(8):701-704.
6. Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood). 2012;31(4):750-759.
7. Carreyrou J, Tamman M. A device to kill cancer, lift revenue. Wall Street Journal . December 7, 2010. http://online.wsj.com/article/ SB10001424052748703904804575631222900534954.html?KEYWORDS= device+to+kill+ cancer+lift+revenue+john+carreyrou+maurice+tamman+ december+7+2010. Accessed May 1, 2013.
8. Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res. 2012;18(24):6742-6747.
9. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162-200.
10. Heidenreich A, Bellmunt J, Bolla M, et al European Association of Urology. EAU guidelines on prostate cancer: part 1, screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61-71.
11. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA . 2005;293(17):2095- 2101. (Pubitemid 40617061)
12. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-131.
13. Altekruse SF, Kosary CL, Krapcho M, eds, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
14. Klabunde CN, Potosky AL, Legler JM,Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol . 2000;53(12):1258-1267. (Pubitemid 32007842)
15. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
16. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conser-vative management. JAMA. 2009;302(11):1202-1209.
17. Gross CP,McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med. 2006;145(9):646-653. (Pubitemid 46768839)
18. Buhlmann P, Yu B. Analyzing bagging. Ann Stat. 2002;30(4):927-961. (Pubitemid 37095335)
19. Allison PD. Logistic Regression Using SAS: Theory and Application. Cary, NC: SAS Institute; 1999.
20. Smedley BD, Stitch AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
21. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001;345(2):99-106. (Pubitemid 32634569)
22. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
23. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the costeffectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys . 2006;66(2):408-415. (Pubitemid 44332736)
24. Grossfeld GD, Chang JJ, Broering JM, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol . 2001;165(3):851-856. (Pubitemid 32156294)
25. Carter HB, Partin AW, Walsh PC, et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012;30(35):4294-4296.
26. Mell LK, Mehrotra AK, Mundt AJ. Intensitymodulated radiation therapy use in the US, 2004. Cancer. 2005;104(6):1296-1303. (Pubitemid 41278966)
27. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer . 2007;109(9):1777-1783. (Pubitemid 46668540)
28. Ries LAG, Krapcho M, Stinchcomb DG, eds, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
29. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
30. Schröder FH, Hugosson J, Roobol MJ, et al ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
31. Chamie K, Daskivich TJ, Kwan L, et al. Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med . 2012;27(5):492-499.
32. Krahn MD, Bremner KE, Asaria J, et al. The tenyear rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60(2):258-263. (Pubitemid 34831769)
33. Kim SP, Karnes RJ, Nguyen PL, et al. A national survey of radiation oncologists and urologists on active surveillance for low-risk prostate cancer. J Clin Oncol. 2012;30(suppl):4657.
34. Observation or radical treatment in patients with prostate cancer. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00499174. Accessed May 31, 2013.
35. Fendrick AM, Martin JJ, Weiss AE. Value-based insurance design: more health at any price. Health Serv Res. 2012;47(1 pt 2):404-413.